沙利度胺对洛哌丁胺治疗失败的化疗相关性腹泻的疗效观察被引量：6

Clinical curative effects of thalidomide on chemotherapy-induced diarrhea refractory to loperamide

下载PDF

导出

摘要目的:探讨沙利度胺对洛哌丁胺治疗失败的化疗相关性腹泻(CID)的临床疗效和安全性。方法:对35例洛哌丁胺治疗失败的3级CID肿瘤患者采用沙利度胺片进行治疗,口服100 mg,每日2次,每隔24 h观察一次疗效。结果:所有患者均行客观疗效及安全性评价,总有效率为77.1%(27/35),平均有效缓解时间为3.1 d;8例(22.9%)评价为无效。9例(25.7%)患者出现乏力、困倦,3例(8.6%)患者出现恶心,2例(5.7%)患者出现皮疹,均为轻度。结论:采用沙利度胺治疗洛哌丁胺无效的CID是一种安全、有效的方法。 Objective:To discuss the clinical curative effects and safety of Thalidomide in the management of chemothera-py-induced diarrhea(CID)refractory to Loperamide.Methods:All35patients with grade3CID tumors who failed loperadine treatment was treated by thalidomide tablets,oral,100mg,twice a day,to observe the effect every24h.Results:All patients re-ceived the evaluation of objective curative effects and safety.The total effective rate was77.1%(27/35)and the average effec-tive release time was3.1d.The effects in8cases(8.6%)were evaluated as invalid.9cases(25.7%)experienced mild drowsiness,fatigue.Mild nausea occurred in3cases(8.6%),and2cases(5.7%)appeared mild rash.Conclusion:Thalido-mide treatment of loperamide ineffective CID is a safe and effective method.

作者高明珠轩菡王进有 GAO Minzhu;XUAN Han;WANG Jinyou(The Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China)

机构地区安徽医科大学第二附属医院

出处《临床医药实践》 2018年第2期83-85,共3页 Proceeding of Clinical Medicine

关键词沙利度胺化疗相关性腹泻洛哌丁胺治疗失败 thalidomid chemotherapy - induced diarrhea refractory to loperamide

分类号 R730.5 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1王彩玲,王俊生.IP方案联合沙利度胺二线治疗晚期小细胞肺癌的临床观察[J].实用癌症杂志,2011,26(1):89-90. 被引量：28
2花道金,冯婷婷,韩正祥,冯守信.沙利度胺对伊立替康所致迟发性腹泻的防治作用临床观察[J].徐州医学院学报,2014,34(2):107-109. 被引量：2
3张程亮,向道春,吕操,徐艳娇,李喜平,刘东.沙利度胺对伊立替康所致腹泻的治疗作用及机制[J].中国医院药学杂志,2012,32(11):840-844. 被引量：6

二级参考文献33

1J - kman DM, Johnson BE. Small cell lung cancer[ J ]. Lancet,2005, 366 (9494) : 1385.
2Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treat- merit of colorectal cancer:clinical overview(J). J Clin Oncol,2001,19 (5) :1501.
3Hirose T,Horiehi N, Ohmofi T,et al. Phase Ⅱ study of irinoteean and earboplatin in patients with the refractory or relapsed small cell lung cancer [ J ]. Lung Cancer,2003,40 ( 3 ) :333.
4Jagasia MH,Langer C J, Johnson DH, et al. Weekly irinotecan and cis- platin in advanced non - small cell lung cancer: A muhicenter phase 11 study[ J]. Clin Cancer Res,2001,7 ( 1 ) :68.
5Kenyon BM. Effects of thalidom ide and related metabolites in a mouse comeal of nevoscularization [ J ]. Exp Eye Res, 1997,64:971.
6Or R. Thalidomide reduces vascular density in granulationtissue of subcutaneously implantsd polyvingyl alcohol pongees in guinea pigs [ J ]. Exp Hematol, 1998,26 : 217.
7Nishiwaki Y, Kawahara M. Irinotecan plus cisplatin complatin corn- pared with etoposide pule cisplatin for extehsive small cell lung cancer [J]. N Engl J Med,2002,346(2) :126.
8Puduvalli VK,Giglio P,Groves MD,et al. Phase Ⅱ trial of iri notecan and thalidomide in adults with recurrenl glioblastoma muhiforme[J]. Neuro Oncol,2008,11)(2):216- 222.
9Jazieh AR, Komrokji R,Gupta A,et al. PhaseⅡ trial of thalid omide,irinotecan and gemcitahine in chemonaive patients with advanced non-small cell lung eancer[J]. Cancer lnvest,2009,27 (9) :932-936.
10Muehlbauer PM, Thorpe D, Davis A, et al. Putting evidence in to practice= evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy induced diarrhea [J]. Clin J Oncol Nurs,211{19,13(3) :336- 341.